TrialCNS drugs2024

A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder.

Masaki Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.